Amalgamated Bank Vertex Pharmaceuticals Inc Transaction History

Amalgamated Bank

  • $12.1 Billion
  • Q3 2024

A detailed history of Amalgamated Bank transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Amalgamated Bank holds 56,190 shares of VRTX stock, worth $29 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
56,190
Previous 53,807 4.43%
Holding current value
$29 Million
Previous $25.2 Million 3.62%
% of portfolio
0.22%
Previous 0.21%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024
BUY
$460.0 - $505.78 $1.1 Million - $1.21 Million
2,383 Added 4.43%
56,190 $26.1 Million
Q2 2024

Aug 12, 2024
SELL
$392.81 - $485.53 $707,450 - $874,439
-1,801 Reduced 3.24%
53,807 $25.2 Million
Q1 2024

Apr 23, 2024
SELL
$407.69 - $446.08 $3.64 Million - $3.98 Million
-8,932 Reduced 13.84%
55,608 $23.2 Million
Q4 2023

Feb 06, 2024
SELL
$343.0 - $410.68 $1.25 Million - $1.5 Million
-3,649 Reduced 5.35%
64,540 $26.3 Million
Q3 2023

Nov 08, 2023
SELL
$338.18 - $362.46 $2.79 Million - $2.99 Million
-8,261 Reduced 10.81%
68,189 $23.7 Million
Q2 2023

Aug 11, 2023
SELL
$314.42 - $351.91 $1.46 Million - $1.64 Million
-4,647 Reduced 5.73%
76,450 $26.9 Million
Q1 2023

May 02, 2023
BUY
$283.23 - $323.1 $3.17 Million - $3.61 Million
11,188 Added 16.0%
81,097 $25.6 Million
Q4 2022

Feb 10, 2023
SELL
$285.76 - $321.48 $1.65 Million - $1.85 Million
-5,767 Reduced 7.62%
69,909 $20.2 Million
Q3 2022

Nov 09, 2022
BUY
$273.83 - $305.53 $1.8 Million - $2.01 Million
6,579 Added 9.52%
75,676 $21.9 Million
Q2 2022

Aug 15, 2022
SELL
$234.96 - $292.55 $68,608 - $85,424
-292 Reduced 0.42%
69,097 $19.5 Million
Q1 2022

Jun 30, 2022
SELL
$221.42 - $260.97 $395,234 - $465,831
-1,785 Reduced 2.51%
69,389 $18.1 Million
Q4 2021

Feb 15, 2022
BUY
$177.01 - $223.45 $1.04 Million - $1.32 Million
5,885 Added 9.01%
71,174 $15.6 Million
Q3 2021

Oct 29, 2021
SELL
$181.39 - $202.99 $481,046 - $538,329
-2,652 Reduced 3.9%
65,289 $11.8 Million
Q2 2021

Aug 16, 2021
BUY
$187.49 - $221.1 $9.74 Million - $11.5 Million
51,971 Added 325.43%
67,941 $13.7 Million
Q1 2021

May 13, 2021
SELL
$207.02 - $241.31 $157,749 - $183,878
-762 Reduced 4.55%
15,970 $3.43 Million
Q4 2020

Feb 12, 2021
SELL
$207.01 - $276.09 $19,251 - $25,676
-93 Reduced 0.55%
16,732 $3.95 Million
Q3 2020

Oct 30, 2020
SELL
$255.65 - $303.1 $127,058 - $150,640
-497 Reduced 2.87%
16,825 $4.58 Million
Q2 2020

Aug 10, 2020
SELL
$225.48 - $295.8 $5.87 Million - $7.7 Million
-26,032 Reduced 60.05%
17,322 $5.03 Million
Q1 2020

May 13, 2020
SELL
$199.77 - $247.81 $209,958 - $260,448
-1,051 Reduced 2.37%
43,354 $10.3 Million
Q4 2019

Feb 13, 2020
BUY
$166.71 - $223.91 $296,076 - $397,664
1,776 Added 4.17%
44,405 $9.72 Million
Q3 2019

Nov 13, 2019
BUY
$166.23 - $187.09 $1.43 Million - $1.61 Million
8,614 Added 25.32%
42,629 $7.22 Million
Q2 2019

Aug 14, 2019
SELL
$164.61 - $190.37 $714,242 - $826,015
-4,339 Reduced 11.31%
34,015 $6.24 Million
Q1 2019

May 15, 2019
BUY
$163.73 - $194.7 $133,439 - $158,680
815 Added 2.17%
38,354 $7.06 Million
Q4 2018

Feb 15, 2019
SELL
$151.91 - $192.21 $155,555 - $196,823
-1,024 Reduced 2.66%
37,539 $6.22 Million
Q3 2018

Nov 14, 2018
SELL
$167.73 - $192.74 $202,785 - $233,022
-1,209 Reduced 3.04%
38,563 $7.43 Million
Q2 2018

Jul 18, 2018
BUY
$145.72 - $169.96 $419,673 - $489,484
2,880 Added 7.81%
39,772 $6.76 Million
Q1 2018

May 22, 2018
BUY
$151.6 - $177.13 $549,246 - $641,741
3,623 Added 10.89%
36,892 $6.01 Million
Q4 2017

Feb 13, 2018
BUY
$137.28 - $155.55 $400,994 - $454,361
2,921 Added 9.63%
33,269 $4.99 Million
Q3 2017

Nov 09, 2017
BUY
$148.13 - $162.24 $4.5 Million - $4.92 Million
30,348
30,348 $4.61 Million

Others Institutions Holding VRTX

# of Institutions
1,717
Shares Held
226M
Call Options Held
1.19M
Put Options Held
1.56M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email